- Home
- CRDF vs ONL Comparison
CRDF vs ONL Comparison
Compare CRDF & ONL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRDF
- ONL
- Stock Information
- Founded
- CRDF 1999
- ONL 2021
- Country
- CRDF United States
- ONL United States
- Employees
- CRDF N/A
- ONL N/A
- Industry
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- ONL Real Estate Investment Trusts
- Sector
- CRDF Health Care
- ONL Real Estate
- Exchange
- CRDF Nasdaq
- ONL Nasdaq
- Market Cap
- CRDF 152.3M
- ONL 169.5M
- IPO Year
- CRDF N/A
- ONL N/A
- Fundamental
- Price
- CRDF $2.15
- ONL $2.44
- Analyst Decision
- CRDF Strong Buy
- ONL Hold
- Analyst Count
- CRDF 4
- ONL 1
- Target Price
- CRDF $10.63
- ONL N/A
- AVG Volume (30 Days)
- CRDF 723.0K
- ONL 194.0K
- Earning Date
- CRDF 11-06-2025
- ONL 11-06-2025
- Dividend Yield
- CRDF N/A
- ONL 3.27%
- EPS Growth
- CRDF N/A
- ONL N/A
- EPS
- CRDF N/A
- ONL N/A
- Revenue
- CRDF $501,000.00
- ONL $150,051,000.00
- Revenue This Year
- CRDF N/A
- ONL N/A
- Revenue Next Year
- CRDF N/A
- ONL N/A
- P/E Ratio
- CRDF N/A
- ONL N/A
- Revenue Growth
- CRDF N/A
- ONL N/A
- 52 Week Low
- CRDF $1.90
- ONL $1.46
- 52 Week High
- CRDF $5.64
- ONL $4.30
- Technical
- Relative Strength Index (RSI)
- CRDF 43.50
- ONL 39.99
- Support Level
- CRDF $2.06
- ONL $2.28
- Resistance Level
- CRDF $2.33
- ONL $2.64
- Average True Range (ATR)
- CRDF 0.11
- ONL 0.11
- MACD
- CRDF -0.01
- ONL -0.00
- Stochastic Oscillator
- CRDF 25.00
- ONL 30.95
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.
About ONL Orion Office REIT Inc.
Orion Properties Inc is a internally-managed REIT engaged in the ownership, acquisition, and management of a diversified portfolio of mission-critical and headquarters office buildings located in high quality suburban markets across the U.S. and leased on a single-tenant net lease basis to creditworthy clients. The portfolio of the company includes traditional office buildings, governmental offices, medical offices, laboratories, and others. The Company operates in one business segment: direct ownership and operation of commercial real estate.